← All stocks

Biomea Fusion, Inc.

BMEA Net buying
CIK 0001840439 #4332 in the set updated 22 Sep 2026
Bought (120 mo)
$36.23M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$26.55M
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$26.55M
9 of 9 sales
Net
+$9.68M
+$9.68M against sales at will

By person

9 insiders · 31 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Chen Bihua
Former Director
$27.30M (2)
+$27.30M
6,741,744
$9.66M
+112.6%
A2A Pharmaceuticals, Inc. entity
10% owner
$805.50K (2)
$26.55M (9)
−$25.75M
3,500,000
$5.02M
−11.7%
Erdtmann Rainer M
See Remarks
$3.72M (7)
+$3.72M
5,108,369
$7.32M
+5.3%
Butler Thomas Andrew
Chief Executive Officer
$3.62M (4)
+$3.62M
4,676,078
$6.70M
+5.1%
Stergiopoulos Sotirios
Director
$379.85K (1)
+$379.85K
4,400,000
$6.31M
+0.8%
Hitchcock Michael J.M.
Interim CEO
$239.43K (3)
+$239.43K
115,000
$164.83K
Valle Franco
Chief Financial Officer
$173.41K (3)
+$173.41K
42,995
$61.62K
Frias Juan Pablo
Chief Medical Officer
349
$500.22
Biomea Health, LLC entity
10% owner
0
$0.00
−100.0%

No percentages here. This company's share count has moved by a factor of 2.0 over the window, from 36,238,687 to 72,483,852 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Erdtmann Rainer M
11 Dec 2025
See Remarks
Buy
30,000
$1.43
$43.00K
Hitchcock Michael J.M.
2 Dec 2025
Interim CEO
Buy
100,000
$0.99
$99.18K
Erdtmann Rainer M
1 Dec 2025
See Remarks
Buy
10,000
$1.05
$10.50K
Erdtmann Rainer M
28 Nov 2025
See Remarks
Buy
40,000
$1.10
$44.05K
Hitchcock Michael J.M.
30 Sep 2024
Director
Buy
10,000
$10.06
$100.60K
Valle Franco
11 Jun 2024
Chief Financial Officer
Buy
12,509
$4.43
$55.36K
Chen Bihua
30 Mar 2023
Director
Buy indirect
400,000
$30.00
$12.00M
Hitchcock Michael J.M.
14 Nov 2022
Director
Buy
5,000
$7.93
$39.65K
Valle Franco
11 Nov 2022
Chief Financial Officer
Buy
4,100
$7.63
$31.29K
A2A Pharmaceuticals, Inc.
16 Aug 2022
10% owner
Buy
30,684
$13.87
$425.65K
Valle Franco
14 Jan 2022
Chief Financial Officer
Buy
10,000
$8.68
$86.77K
Stergiopoulos Sotirios
17 Sep 2021
Director
Buy indirect
34,658
$10.96
$379.85K
A2A Pharmaceuticals, Inc.
17 Sep 2021
10% owner
Buy
34,658
$10.96
$379.85K
Butler Thomas Andrew
23 Aug 2021
CEO
Buy indirect
24,000
$13.20
$316.87K
Erdtmann Rainer M
23 Aug 2021
President & COO
Buy indirect
24,000
$13.20
$316.87K
Butler Thomas Andrew
18 Aug 2021
CEO
Buy indirect
14,000
$10.77
$150.74K
Erdtmann Rainer M
18 Aug 2021
President & COO
Buy indirect
14,000
$10.77
$150.74K
Butler Thomas Andrew
17 Aug 2021
CEO
Buy indirect
14,000
$10.79
$151.07K
Erdtmann Rainer M
17 Aug 2021
President & COO
Buy indirect
14,000
$10.79
$151.07K
Chen Bihua
20 Apr 2021
Director
Buy indirect
900,000
$17.00
$15.30M
Butler Thomas Andrew
15 Apr 2021
CEO
Buy indirect
176,470
$17.00
$3.00M
Erdtmann Rainer M
15 Apr 2021
President & COO
Buy indirect
176,470
$17.00
$3.00M

What was left out

Form 4 filings counted 80
Amendments (4/A) skipped 2
Filings about a different issuer 0
Unreadable filings 0
Joint filings 8
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 9
Transactions with no price 0
Shares from compensation/vesting 6,782,949
Sales filed before the plan box existed 2
History held since 19 Apr 2021